Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare and Dharmacon, Biolog and Nara Institute of Science and Technology, Becton Dickinson, Charles River Laboratories and GenOway, and Procognia


GE Healthcare to Distribute Dharmacon RNAi Products in Japan

Dharmacon announced last week that GE Healthcare will be the exclusive distributor of its RNAi research products in Japan.

Financial terms of the deal were not disclosed.

Biolog to Phenotype E. Coli Genome with Japanese Organizations

Biolog will collaborate with Japanese university Nara Institute of Science and Technology and Japanese software firm Axiohelix to begin broad-scale genotyping of the E. coli genome, the Hayward, Calif.-based company said this week.

Under the terms of the agreement, Biolog will phenotype the E. coli collection developed at the Nara Institute using its Phenotype MicroArray technology. The work will commence at Biolog’s headquarters, with the first 100 genes slated to be analyzed by March 2005. The E. coli genome consists of more than 4,000 genes.

The data from the first 100 strains will be reviewed by Biolog scientists and the Nara Institute, while the information will be organized and catalogued Axiohelix. The groups expect the rest of the genome to be phenotyped in 2005, Biolog said.

BD Board Declares Dividend; Authorizes Share Repurchases

Becton Dickinson’s board of directors last week declared a quarterly dividend of $0.18 per commons share, an increase of $0.03 per share from last quarter. The company anticipates an annual dividend of $0.72 per share at the current rate.

The board also announced that it has authorized BD to repurchase up to 10 million of its common shares, which the company plans to use for general corporate purposes.

Charles River Labs and GenOway to Co-Market Genetically Modified Research Models in Europe

Charles River Laboratories and France-based GenOway will speed availability of genetically modified research models to their customers in Europe, the companies said last week.

Under the terms of the three-year agreement, Charles River Labs will market and promote GenOway’s processes for developing research models, which include gene-expression and gene-inactivation techniques for mouse and rat models, the companies said.

Charles River Labs, which is based in Wilmington, Mass., said that it will market GenOway’s technology to clients of its European Transgenic Services business. GenOway is based in Lyon.

Financial terms of the deal were not disclosed.

Procognia Raises $23.5M in Funding

UK-based Procognia, which develops and manufactures analytical devices for use by drug manufacturers, has raised $23.5 million in funding led by Apax Partners with an investment of some $10 million and including new investor Star Ventures. Previous investors Evergreen and Koor CVC also participated in the round.

Procognia is commercializing a platform it acquired in 2002 when it purchased British biotechnology company Sense Proteomic, which is developing technology to analyze the biological funcction of proteins using chips. In early November, Procognia announced a deal with Sigma Aldrich to market its protein chip technology.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.